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Methicillin-resistant Staphylococcus aureus nasal carriage and infec-
tions in CAPD. In view of the increasing concern about methicillin-
resistant Staphylococcus aureus (MRSA) infections, we studied the
characteristics and outcome of MRSA nasal carriage and infections in
our CAPD program. All patients entering into the CAPD program from
January 1989 to December 1991 were enrolled into the study, The
patients' anterior nares were cultured before the implantation of the
catheters, Peritoneal dialysis-related infections were diagnosed based
on standard criteria. Data on MRSA nasal carnage, exit-site and tunnel
infections and peritonitis were prospectively collected. A total number
of 167 patients with 225.9 patient dialysis years were studied with a
mean follow-up duration of 16.2 9.5 months. There were 28 patients
with MRSA nasal carriage. The carrier state was unrelated to age, sex
and presence of diabetes mellitus. MRSA nasal carriage was associated
with a significant increase in the rate of peritonitis (P <0.01) and
exit-site infections (P <0.01), the number of catheter losses, and CAPD
patient dropout (P < 0.001). A total of 30 patients had MRSA infec-
tions. In this group, 15 patients had 24 episodes of peritonitis; 20 had 22
episodes of exit-site infections; and 1 had tunnel infection. Fourteen
patients had a combination and/or multiple episodes of infections.
Treatment of MRSA infections with intraperitoneal vancomycin was
unsuccessful in 12 patients (40.0%) resulting in catheter loss. Nine
patients (30.0%) dropped out of CAPD after treatment failure for MRSA
peritonitis. The patient dropout rate per infection for MRSA infections
was comparable to Pseudomonas and fungal infections, but was signif-
icantly higher than MSSA infections (P < 0.005). We conclude that
MRSA nasal carriage is associated with an increased risk of CAPD-
related infections. MRSA peritonitis is an important cause of CAPD
failure.
Chronic ambulatory peritoneal dialysis (CAPD) has become a
standard mode of therapy for end-stage renal disease. Infec-
tions related to the peritoneal catheter and peritonitis are the
most common complications in patients on chronic peritoneal
dialysis causing catheter loss and failure of CAPD [1]. Methi-
cillin-resistant Staphylococcus aureus (MRSA) infections cause
significant patient morbidity and mortality, particularly in the
hospital environment [2, 3]. More recently, community-ac-
quired MRSA infections have been documented [4, 5]. In the
CAPD patient population, there also appears to be an increasing
problem with methicillin-resistant staphylococcal infections.
Recent reports have focused on methicillin-resistant coagulase-
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negative staphylococcal infections [61, but there is little infor-
mation on MRSA infections. We prospectively studied all
patients with MRSA nasal carriage and infections in our CAPD
program over a three year period to assess MRSA characteris-
tics and treatment outcome.
Methods
Patient population and study design
All patients entering into the hospital's CAPD program were
studied. Swabs were taken from the anterior flares 24 to 48
hours before the insertion of the Tenckhoff catheter and re-
peated four and eight weeks after commencing CAPD. Catheter
implantation was performed by the same surgeons using the
traditional paramedian approach and double-cuffed straight
Tenckhoff catheters. The patients were reviewed at each out-
patient clinic visit by the physicians for exit-site and tunnel
infections and peritonitis. The patients were also instructed to
report to the CAPD center whenever there was any catheter,
exit-site or peritoneal fluid abnormality. Data on all episodes of
peritonitis, exit-site and tunnel infections were prospectively
gathered for microbial culture and sensitivity results, and
treatment outcome. Data on MRSA CAPD-related infections
were specifically noted. The patients were followed up until
December 1991 or until discontinuation of CAPD, if earlier.
Culture and antibiotic sensitivity methods
Nasal cultures were taken by rotating rayon swabs in the
anterior nares of the patients. All cultures from suspected
exit-site and tunnel infections were also taken with similar
swabs. Specimens were transported to the hospital's microbi-
ology laboratory in Amies transport media, inoculated onto 7%
horse blood agar and enrichment media, and incubated aerobi-
cally at 37°C for 48 hours. Gram-positive coagulase-positive
cocci isolated from the blood agar plates were identified as S.
aureus using standard techniques [7]. Isolates were transferred
to 5% sodium chloride Mueller-Hinton plates containing a 5
mg/liter methicillin disc and incubated for 18 hours at 35°C.
Methicillin resistance was verified based on standard interna-
tional criteria [8]. Antimicrobial susceptibility testings for other
antimicrobial agents were performed using the Kirby-Bauer
method [9].
At presentation of peritonitis, at least 50 ml of dialysis
effluent was despatched to the microbiology department for
aerobic and anaerobic cultures on blood agar and MacConkey
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plates. Methicillin-susceptible S. aureus and MRSA were de-
tected as above. Phage typing was not performed.
Definitions of nasal carriage, infections and treatment
outcome
A patient was considered to be an MRSA or MSSA nasal
carrier when either MRSA or MSSA was cultured from the
anterior nares on at least two separate occasions. A heavy
carriage was defined as a positive direct culture, and a light
carriage was defined as a negative direct culture but a positive
culture on enrichment media. A negative culture was defined as
when either MRSA or MSSA could not be isolated by either
direct or enrichment culture [10].
The diagnosis of an exit-site infection was based on pericath-
eter cutaneous erythema and/or drainage with or without a
positive culture. An exit-site with a surrounding crust was not
considered an infection, and a positive culture in the absence of
signs of inflammation was considered as colonization. A tunnel
infection was defined as erythema, induration and/or tenderness
over the subcutaneous catheter tract with or without discharge
and a positive culture. Exit-site and tunnel infections were
classified as catheter-related infections.
Peritonitis was defined as cloudy peritoneal effluent with
greater than 100 leukocytes per cubic millimeter of fluid and
more than 50% polymorphonuclear cells. Catheter-related in-
fections and peritonitis were considered to be related if the two
infections occurred simultaneously or followed each other
within two weeks of treatment. The pathogens isolated had to
be either the same in both infections or one yielding a negative
culture. Peritonitis, exit-site and tunnel infections were classi-
fled as CAPD-related infections.
Success of treatment of catheter-related infections and peri-
tonitis was defined as resolution of signs and symptoms of
infections, clearing of the dialysate and a negative culture;
failure of treatment was defined as the persistence of infection
despite adequate and appropriate antimicrobial and adjunctive
treatment. This could include external cuff shaving for exit-site
infections. A relapse was defined as infection occurring either
with the same organism or a negative culture within 14 days of
stopping treatment. A new infection was defined as infection
occurring more than 14 days after stopping treatment or an
infection with a new organism.
Treatment of exit-site infection, tunnel infection, and
peritonitis
Peritonitis was treated with intraperitoneal antibiotics for 14
days. The choice of antibiotic and the duration of treatment
were tailored according to the culture reports and clinical
response of the patient. Generally, the treatment of MSSA,
MRSA and other gram positive peritonitis and catheter-related
infections consisted of intraperitoneal vancomycin at a dose of
one gram given weekly for two weeks. Dialysis was continued
during the treatment. Gram negative infections were treated
using intraperitoneal aminoglycosides and/or third generation
cephalosporins, depending on the antibiotic sensitivity of the
organism isolated. The external cuff of the catheter was exte-
riorized and shaved if the exit-site infection persisted after two
weeks of treatment. Antibiotics was continued for another two
weeks. The peritoneal catheter was removed for failure of
Table 1. Demographic and clinical data of patients with and without
MRSA nasal carriage
Characteristic
MRSA
carriers
Non-
carriers
P
value
No. of patients 28 139
Mean age SEM years 56.2 1.1 55.5 2.3
Sex (MIF) 11/17 63/76
DM/non-DM 20/8 77/62
Duration of follow-up 16.5 0.8 14.9 1.6
means SEM, months
MRSA peritonitis rate 0.43 0.05 <0.01
episodes/patient/year
MRSA exit-site infection rate 0.40 0.05 <0.01
episodes/patient/year
Multiple/combination of CAPD- 8 6 <0.001
related MRSA inf'ecitons
Catheter lossa 11 3 <0.001
CAPD patient dropout" 9 1 <0.001
Abbreviation is DM, diabetes mellitus.
,b Catheter losses and CAPD patient dropouts are secondary to
therapy and for relapsing peritonitis or catheter-related infec-
tions. The nasal carriage of MRSA and exit-site colonization
were not treated.
Statistical analysis
After fulfilling the criteria of nasal carriage, the patients were
considered as either MRSA carriers or noncarriers for the entire
duration of follow-up. Infections rates were analyzed using two
statistical techniques. Peritonitis and exit-site infection-free
survival curves (time to first episode) were constructed accord-
ing to the Kaplan-Meier method and compared using the log
rank test [11]. Infections rates were determined by dividing the
total number of episodes by the time on dialysis for that period.
After the data had been shown to fit into a gamma Poisson-
based (negative binomial) model, it was used to compare the
number of infections/treatment time/patient and to calculate the
probability of remaining free of infection at the end of one year
[12, 13]. Contingency tables were analyzed using the chi-square
test and continuous variables were compared using Student's
t-test. All P values were two-tailed and a P value of less than or
equal to 0.05 was considered significant. Data where appropri-
ate were presented as mean values SEM.
Results
Patient characteristics
During the period from January 1989 to December 1991, 167
patients with 225.9 patient dialysis years were studied. Twenty-
eight patients (16.8%) entered the study as MRSA nasal carriers
and 139 patients (83.2%) as noncarriers. All the carriers had
heavy MRSA nasal carriage. The mean age in the carrier and
noncarrier groups were 56.2 and 55.5 years, respectively.
MRSA nasal carriage was unrelated to age or sex of the patient.
Although there were more patients with diabetes mellitus as the
cause of end-stage renal disease in the carrier group, the
difference was not statistically significant ( = 2.46, P = NS).
Table 1 summarizes the demographic data of the two groups of
patients.
All the patients had the Tenckhoff double-cuffed catheters
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implanted. The break-in techniques and long-term exit-site care
were similar in both groups. The catheter break-in technique
was either the use of small volume exchanges in the recumbent
position in the immediate postoperative period, or resting of the
catheter with hemodialysis in the interim period. The patient
was commenced on CAPD exchanges two weeks after catheter
implantation. Long-term exit-site care consisted of the use of
povidone-iodine and nonocciusive, sterile gauze dressings. All
the patients employed the Baxter ultraviolet germicidal ex-
change device for their CAPD exchanges.
There were six deaths in the carrier group and 32 in the
noncarrier group. Eight patients in the carrier group were
transferred to hemodialysis and two patients had recovery of
renal function. Nineteen noncarriers were transferred to hemo-
dialysis, two patients underwent transplantation and two pa-
tients had recovery of renal function.
Rates of CAPD-related infections
The infection rates for peritonitis and exit-site are shown in
Table 1. Life table analysis showed that MRSA nasal carriage
led to a significantly increased risk of exit-site infections (P <
0.01) and peritonitis (P < 0.05; Fig. 1). Poisson-based regres-
sion analysis showed that the risk of being free from MRSA
peritonitis after a year on CAPD in the carrier group was 65%
versus 96% in the noncarrier group (P < 0.01). Similarly, the
risk of being free from an MRSA exit-site infection after a year
on CAPD was 67% in a carrier as opposed to 96% in a
noncarrier (P < 0.01). Finally, the number of patients who had
a combination of CAPD-related infections or multiple episodes
of peritonitis was significantly higher in the carrier group than in
the noncarrier group (P < 0.001; Table 1).
Catheter loss and CAPD dropout
Catheters were removed because of MRSA infections in
eleven patients in the carrier group and three patients in the
noncarrier group (P <0.001). Two patients in the carrier group
who had second catheters reimplanted eventually lost the
catheters because of peritonitis. Both were transferred to
hemodialysis because of peritoneal failure. Nine patients in the
carrier group dropped out of CAPD and transferred to hemodi-
alysis because of MRSA peritonitis, compared to only one in
the noncarrier group (P < 0.001). All nine patients failed
reimplantation of their catheters for CAPD because of perito-
neal adhesions. The results are shown in Table 1. Two patients
each from the carrier and noncarrier groups successfully under-
went second catheter reimplantation and resumed CAPD. All
four patients had their catheters removed because of catheter-
related infections.
MRSA infections
Data on 30 patients with peritoneal dialysis-related MRSA
infections are shown in Table 2. Methicillin-resistant S. aureus
was the organism isolated in 12.9% of the total episodes of
peritonitis and 29.7% of catheter-related infections. The mean
(± SEM) age was 56.3 1.6 years with a mean follow-up of 19.6
months (range 5 to 31 months). In this group, 17 patients
(56.7%) were MRSA carriers and 13 patients (43.3%) were
noncarriers. There were 15 patients with 24 episodes of MRSA
peritonitis, 20 patients with 22 episodes of exit-site infections
and one patient had a tunnel infection. Fourteen patients
(46.7%) had a combination and/or multiple episodes of infec-
tions. There were no deaths which were secondary to MRSA
infections.
Treatment of exit-site infections with vancomycin was suc-
cessful in 13 of 20 (65.0%) patients. Three patients required
external catheter cuff shaving as adjunctive treatment. Exit-site
infection did not recur in these three patients. Another three
patients required catheter removal for failure of treatment of
exit-site infection, however, all of them had their catheters
reimplanted and returned to CAPD. One patient with an exit-
site and tunnel infection failed antibiotic therapy, but later
returned to CAPD.
MRSA peritonitis was associated with a high failure rate.
Nine of 15 patients (60%) with MRSA peritonitis were refrac-
tory to treatment resulting in catheter loss. All of them failed
attempted reimplantation of their catheters because of perito-
neal adhesions.
The poor response to therapy of MRSA infections had a
significant impact on CAPD patient dropout. In our center,
MRSA CAPD-related infections was the most important cause
of patient dropout and transfer to hemodialysis. Although
MRSA as an organism accounted for only 16.1% of CAPD-
related infections, it was responsible for 34.6% of the total
CAPD patient dropout.
Table 3 showed the demographic and clinical data of patients
who were either MRSA or MSSA carriers. The infection rates
and clinical outcomes were secondary to the respective organ-
isms of the carriers. No significant differences were seen in the
peritonitis and exit-site infection rates and the number of
infections between MRSA and MSSA carriers. However, the
number of catheter losses (11 of 28 vs. 6 of 35, P = 0.05) and
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Fig. 1. Life-table analysis of the time to first episode of MRSA
peritonitis (P) and exit-site infection (ES). Symbols are: (—) MRSA
noncarrier P; (.- — .-) MRSA noncarrier ES; (—) MRSA carrier P;
(--- -) MRSA carrier ES. Patients who are MRSA carriers are signifi-
cantly at risk of MRSA peritonitis (P < 0.05) and exit-site infection (P
<0.01).
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Table 2. Patients with MRSA infections: Characteristics and
outcomes
Pt.
Age
year
Total
CAPD
months
MRSA
carrier
status
DM
status
Type of
infection
Time from
CAPD
months
Treatment
outcome
1 59 28 Yes No ES 6, 20 Success
2 72 16 Yes No ES/P 1 F/CO/HD
3 42 30 Yes No ES 7, 21 Success
4 48 29 Yes Yes P 11 Success
5 51 9 Yes Yes ES S F/CO/CAPD
6 65 6 Yes No ES 3 Success
7 52 5 Yes Yes P
P
3
5
Success
F/CO/HD
8 56 16 Yes No ES 1 Success
9 32 5 Yes Yes P
P
1
5
Success
F/CO/HD
10 53 8 Yes No ES/P
P
1
6
F/CO/CAPD
F/CO/HD
11 59 12 Yes No P 12 F/CO/HD
12 61 12 Yes Yes ES
P
P
I
6
8
F/CO/CAPD
Success
F/CO/HD
13 57 12 Yes Yes ES/P 9 F/CO/HD
14 63 32 Yes Yes ES 1 CS/Success
15 41 20 Yes Yes ES x 2 12, 17 Success
16 61 28 Yes Yes ES 1 CS/Success
17 59 18 Yes Yes P
P
12
17
Success
R/CO/HD
18 57 12 No No ES/P 9 Success
19 65 30 No Yes ES x 2 1, 7 Success
20 63 23 No Yes P x 3 12, 15, 20 Success
21 43 23 No Yes P x 2 6, 10 Success
22 65 26 No Yes P
P
20
26
Success
F/CO/HD
23 66 12 No Yes ES/T 3 F/CO/CAPD
24 59 31 No Yes ES 1 Success
25 49 27 No Yes P 21 Success
26 58 30 No Yes ES 1 CS/Success
27 57 23 No No ES 3 Success
28 65 22 No No ES 16 Success
29 51 24 No No ES 1 F/CO/CAPD
30 61 20 No No P 13 Success
Abbreviations are: ES, exit-site; T, tunnel; P, peritonitis; F, failure;
R, relapse; CO/HD, catheter removed and patient converted to hemo-
dialysis; CO/CAPD, catheter removed but patient returned to CAPD.
a Duration of CAPD before onset of infection
CAPD patient dropouts (9 of 28 vs. 2 of 35, P < 0.01) were
significantly higher for MRSA infections in MRSA carriers
compared to MSSA infections in MSSA carriers.
Finally, we compared the patient dropout rate per infection
for MRSA infections with other organisms (Table 4). Methicil-
lin-resistant S. aureus, Pseudomonas aeruginosa and fungal
infections had the same patient dropout rate per infection of
0.21 to 0.25. Although MSSA infections were treated using the
same antibiotic regimen, the patient dropout rate per infection
was significantly lower for MSSA than MRSA infections (P <
0.05 by chi-square test).
Discussion
Methicillin-resistant S. aureus was first reported in 1961 after
the availability of methicillin for therapeutic use [14]. Since
then, there have been numerous reports on outbreaks of MRSA
infections both in the hospital as well as in the community [1-4].
Holley et al reported a series of 15 patients with methicillin-
Table 3. Demographic and clinical data of patients with MRSA or
MSSA nasal carriage
Characteristic
MRSA
carriers
MSSA
carriers
No. of patients 28 35
Mean age SEM years 56.2 1.1 54.9 1.0
Sex(M/F) 11/17 15/20
Duration of follow-up 16.5 0.8 19.8 1.2
mean SEM, months
Infection rate
Peritonitis episodes/patient/year 0.43 0.36
Exit-site infection episodes/patient/year 0.40 0.28
Clinical outcome
Multiple/combination of CAPD related 8 9
infections
Catheter loss 11 6
CAPD patient dropout 9 2"
Death 0 I
Infection rates and clinical outcomes occurring in MRSA and MSSA
carriers are caused by MRSA and MSSA organisms, respectively.
a p = 0.05, "P < 0.01
Table 4. CAPD-related infections and patient dropout
Organism
CAPD
patient
dropouta(N = 26)
CAPD-
related
infectionst
(N = 260)
Patient
dropout
rate per
infectionc
no. (%)
Methicillin-susceptible
Staphylococcus aureus
Methicillin-resistant
Staphylococcus aureus
Coagulase-negative
Staphylococcus
Pseudomonas aeruginosa
Coliforms
Fungus
Others
2 (7,7)
9 (34.6)
1 (3.9)
4 (15.4)
4 (15.4)
3 (11.5)
3 (11.5)
63 (24.2)
42 (16.2)
22 (8.5)
17 (6.5)
30 (11.5)
12 (4.6)
74(28.5)
0.03'
021d
0.04
0.23
0.13
0.25
0.04
a Total number of CAPD patients who transferred to hemodialysis
because of CAPD related infectionsbTotal number of organisms isolated in CAPD-related infections
Dropout rate per infection = No. of CAPD patient dropout ÷ No.
of CAPD-related infections
d P < 0.05 (chi-square test)
resistant staphylococcal infections, of which three were MRSA
infections [6], and two of the three patients were MRSA nasal
carriers. Holley et a! reported a significant increase in the
percentage of coagulase-negative methicillin-resistant staphylo-
coccal infections from 1984 to 1988. However, MRSA infec-
tions have not been extensively examined in chronic peritoneal
dialysis patients.
Early research had reported a high incidence of S. aureus
nasal carriage rate in patients on hemodialysis [15, 16]. S.
aureus nasal carriage had been shown to be associated with a
higher risk of peritonitis and exit-site infection by the same
organism during CAPD [17—19]. Luzar et al showed that the
chance of remaining free of a S. aureus infection was signifi-
cantly higher in a noncarrier compared to a carrier [20].
Although the patient numbers were smaller, Sewell et a! have
suggested a possible link between the nasal carriage state and
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infections [18]. To our knowledge, data on the effects of MRSA
nasal carriage on CAPD patients are not available.
The objective of our study was twofold: to determine whether
there is a similar link in MRSA nasal carriage and a subsequent
infection, and to study the clinical characteristics and treatment
outcome of MRSA infections. We observed that the MRSA
carriage rate in our patient population was 16.8%. Reports of S.
aureus carriage rates ranged from 10 to 30%, reaching as high as
60% in the hemodialysis population [16, 18, 21]. MRSA carriage
rates in the general population are not available, but among
non-medical hospital personnel MRSA carriage rates ranged
from 0.4 to 8.0% [4, 22, 23]. We postulated that our patients
with MRSA nasal carriage acquired MRSA during one of their
hospital admissions prior to commencing CAPD. Twenty-five
of the 28 MRSA nasal carriers had previous hospital admissions
for medical problems related to chronic renal failure before
commencing dialysis. The other three patients had admissions
to other hospitals before coming to our center. Although none
of the medical and nursing staff in our center who were directly
involved with CAPD patient care were MRSA carriers, it is still
most likely that cross contamination occurred from other med-
ical and non-medical personnel to the patients. Recently, it was
reported that as high as 50% of healthy hospital staff may be
occasional light carriers of MRSA phage types endemic to a
hospital environment [24]. In view of the fact that swabs from
the nares were taken at intervals of four weeks, we observed
that MRSA nasal carriage persisted after the patient's discharge
from the hospital. None of the MRSA carriers detected prior to
implantation of the catheter was clear of carriage after four
weeks. Similar results were reported by Hicks, Moore and
Williams, who showed that the risk of persistence of MRSA
nasal carriage was high and related to the level of carriage. In
their follow-up of 35 families with MRSA carriage, none of the
families with heavy carriage was clear of carriage at the end of
four weeks [10].
The management of MRSA nasal carrier state is difficult.
There is substantial evidence that the use of topical antimicro-
bials and antiseptics is of little or no value. Antimicrobials such
as bacitracin [25], tetracycline [26] or chiorhexidine [27] re-
sulted in the suppression of nasal colonization as opposed to
eradication. Systemic antibiotics such as rifampin [28], fusidic
acid [29] and trimethoprim-sulphamethoxazole [5] have also
been tried. More recently, mupirocin (pseudomonic acid) has
shown promising results [30—32], but randomized trials are
needed to determine its efficacy in CAPD patients. Recently,
cases of mupirocin-resistant S. aureus had been reported [33,
34].
Our study showed that, like MSSA, the MRSA carrier state is
associated with an increased risk of CAPD-related infections.
Patients who were MRSA nasal carriers had both an increased
rate of exit-site infection and peritonitis. MRSA nasal carriers
also suffered an increased number of catheter losses and CAPD
patient dropouts.
Treatment of MRSA peritonitis with intraperitoneal vanco-
mycin was unsuccessful in a high percentage of cases, resulting
in a high CAPD patient dropout rate comparable to Pseudo-
monas aeruginosa and fungal infections. More interesting was
the finding that the patient dropout rate per infection for MRSA
infections was significantly higher than MSSA infections de-
spite the same treatment protocol. The reason for this differ-
ence was unclear, but it may be related to the virulence of the
organism, certain HLA phenotypes of the patients and their
immune response. Certainly, the poor response to vancomycin
therapy for MRSA infections as opposed to MSSA infections
may be a reflection of the different virulence of the two
organisms. Keane, Coleman and Cafferkey suggested that
MRSA was a heterogenous group of organisms and its virulence
depended on the production of a range of extracellular toxins.
Nosocomial MRSA strains which caused infections may belong
to a select group with increased virulence. On the other hand,
French et al [36] argued on clinical evidence that MRSA and
MSSA strains had equal pathogenicity in their center. Thus, it
remains to be determined whether MRSA and MSSA differ in
intrinsic virulence.
Persistent MRSA nasal carriers have been shown to possess
a certain HLA phenotype and it may be possible that eradica-
tion of infection, like eradication of nasal colonization, is
related to the individual's HLA phenotype and his immune
response [37]. In reality, all factors are likely to operate in a
patient with MRSA infection, host characteristics which favor
MRSA carriage of a particular strain also predispose to infec-
tion and may be related to the eradication of infection.
In conclusion, this study shows that MRSA nasal carriage is
associated with an increased risk of exit-site infections and
peritonitis. The presence of MRSA nasal carriage in a patient
should alert the clinician to the high possibility of future MRSA
infections. MRSA exit-site infections appear to respond well to
treatment, but MRSA peritonitis was associated with a high
failure rate and catheter loss. Further work needs to be done to
address the issue of eliminating MRSA nasal carriage and to
improve the treatment of MRSA infections.
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